InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
InMed Pharmicals和其他两只细价股内部人士正在买入
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周四收盘上涨超过450点。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。
GeoVax Labs
GeoVax 实验室
- The Trade: GeoVax Labs, Inc. (NASDAQ:GOVX) President, CEO David A Dodd acquired a total of 8,729 shares an average price of $2.27. To acquire these shares, it cost around $19,781.
- What's Happening: GeoVax is expected to report 2023 financial results on Feb. 29, 2024.
- What GeoVax Labs Does: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
- 交易：GeoVax Labs, Inc.（纳斯达克股票代码：GOVX）总裁兼首席执行官戴维·多德 共收购了8,729股股票 平均价格为2.27美元。收购这些股票的成本约为19,781美元。
- 发生了什么：预计GeoVax将在2024年2月29日公布2023年财务业绩。
- GeoVax Labs做什么：Geovax Labs Inc是一家临床阶段的生物技术公司，使用新的专有平台开发针对传染病和实体瘤癌的人类疫苗和免疫疗法。
Beneficient
受益人
- The Trade: Beneficient (NASDAQ:BENF) Director Peter T Cangany Jr acquired a total of 400,000 shares at at an average price of $0.26. To acquire these shares, it cost around $102,000.
- What's Happening: On Feb. 13, Beneficient posted a wider quarterly loss.
- What Beneficient Does: Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess.
- 贸易：受益人（纳斯达克股票代码：BENF）董事小彼得·坎加尼 共收购了40万股股票 平均价格为0.26美元。收购这些股票的成本约为10.2万美元。
- 发生了什么：2月13日，受益人公布了更大的季度亏损。
- 受益人做什么：Perenicient是一家以技术为基础的金融服务控股公司，该公司（及其子公司）通过其端到端在线平台AltAccess为另类资产行业的参与者提供简单、快速且具有成本效益的流动性解决方案。
InMed Pharmaceuticals
InMed 制药
- The Trade: InMed Pharmaceuticals Inc. (NASDAQ:INM) Director Andrew Hull acquired a total of 37,500 shares at an average price of $0.39. The insider spent around $14,625 to buy those shares.
- What's Happening: InMed Pharmaceuticals, on Oct. 24, said it selected a lead Alzheimer's drug candidate following positive proof-of-concept study data.
- What InMed Pharmaceuticals Does: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company.
- 交易：InMed 制药公司（纳斯达克股票代码：INM）董事安德鲁·赫尔 共收购了 37,500 股股票 平均价格为0.39美元。知情人士花费了约14,625美元购买了这些股票。
- 发生了什么：InMed Pharmaceuticals于10月24日表示，根据积极的概念验证研究数据，它选择了一种主要的阿尔茨海默氏症候选药物。
- InMed 制药公司做什么：InMed Pharmaceuticals Inc是一家总部位于加拿大的临床阶段生物制药公司。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道